We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04456023
Recruitment Status : Withdrawn (This study was cancelled before enrolling any patients for business related reasons.)
First Posted : July 2, 2020
Last Update Posted : March 2, 2022
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : October 31, 2022
Estimated Study Completion Date : September 27, 2027